NEW YORK (GenomeWeb News) – Asuragen has raised $7.5 million toward a targeted $15 million round.

The Austin, Texas-based molecular diagnostics firm disclosed the funding in a document filed this week with the US Securities and Exchange Commission. Company President and CEO Rollie Carlson said that existing investors participated in the raise, which will go toward the commercialization of Asuragen's oncology and genetic disease tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.